This inventor holds 6 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 2006-2023.
Location History:
- Copenahgen O, DK (2006)
- Copenhagen, DK (2017)
- Koebenhavn OE, DK (2018 - 2020)
- Koebenhavn, DK (2018 - 2023)
Company Filing History:
Years Active: 2006-2023
Title: Thue Johansen: Innovator in Diabetes Treatment
Introduction
Thue Johansen is a prominent inventor based in Koebenhavn OE, Denmark. He has made significant contributions to the field of diabetes treatment, holding a total of 6 patents. His work focuses on innovative methods for improving glycemic control and reducing complications associated with diabetes.
Latest Patents
Thue Johansen's latest patents include a method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications. This invention relates to insulin degludec for use in medicine. Another notable patent is a method of treating diabetes mellitus by administering a derivative of a naturally occurring insulin or insulin analogue at specifically defined intervals. This derivative exhibits a prolonged profile of action, providing effective treatment for patients in need.
Career Highlights
Thue Johansen is currently employed at Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. His work at Novo Nordisk has allowed him to focus on developing innovative solutions for diabetes management, contributing to the advancement of medical treatments in this area.
Collaborations
Thue has collaborated with notable colleagues such as Kjell Malmlof and Henriette Mersebach, enhancing the research and development efforts within his field.
Conclusion
Thue Johansen's contributions to diabetes treatment through his innovative patents and work at Novo Nordisk highlight his commitment to improving patient outcomes. His ongoing efforts in this critical area of healthcare continue to make a significant impact.